The Technical Analyst
Oncorus, Inc. [ONCR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Oncorus, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.08% $0.126
America/New_York / 29 des 2023 @ 14:55
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.29 mill |
| EPS: | -3.48 |
| P/E: | -0.0362 |
| Earnings Date: | Mar 22, 2024 |
| SharesOutstanding: | 26.09 mill |
| Avg Daily Volume: | 0.109 mill |
| RATING 2023-12-29 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0362 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0362 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.122 - 0.130 ( +/- 3.17%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-06 | Shea Brian J. | Sell | 0 | Common Stock |
| 2023-06-06 | Shea Brian J. | Sell | 15 000 | Employee Stock Option (right to buy) |
| 2023-06-06 | Shea Brian J. | Sell | 3 744 | Employee Stock Option (right to buy) |
| 2023-06-06 | Shea Brian J. | Sell | 14 700 | Employee Stock Option (right to buy) |
| 2023-06-06 | Shea Brian J. | Sell | 19 100 | Employee Stock Option (right to buy) |
| INSIDER POWER |
|---|
| -36.44 |
| Last 97 transactions |
| Buy: 2 441 000 | Sell: 694 654 |
Forecast:
01:40 - $0.0270
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.126 (-3.08% ) |
| Volume | 0.136 mill |
| Avg. Vol. | 0.109 mill |
| % of Avg. Vol | 125.10 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ONCR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ONCR
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2022-11-23 08:00:00 - Press Release
Oncorus To Participate In Upcoming Investor Conferences
Andover, mass., nov. 23, 2022 (globe newswire) -- oncorus, inc. (nasdaq: oncr), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that president and chief executive officer, theodore (ted) ashburn, m.d., ph.d., will participate in two upcoming investor conferences:
2022-09-26 07:00:00 - Press Release
Oncorus To Present At Chardan's 6th Annual Genetic Medicines Conference
Andover, mass., sept. 26, 2022 (globe newswire) -- oncorus, inc. (nasdaq: oncr), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that president and chief executive officer, theodore (ted) ashburn, m.d., ph.d., will participate in a fireside chat at chardan's 6th annual genetic medicines conference on monday, october 3, 2022 at 2:00 p.m. et in new york, ny.
2022-09-06 07:00:00 - Press Release
Oncorus To Present At The H.c. Wainwright 24th Annual Global Investment Conference
Cambridge, mass., sept. 06, 2022 (globe newswire) -- oncorus, inc. (nasdaq: oncr), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that president and chief executive officer, theodore (ted) ashburn, m.d., ph.d., will participate in a fireside chat at the h.c. wainwright 24th annual global investment conference on monday, september 12, 2022 at 9:00 a.m. et in new york, ny.
2022-06-01 07:00:00 - Press Release
Oncorus To Present At The Jefferies Global Healthcare Conference
Cambridge, mass., june 01, 2022 (globe newswire) -- oncorus, inc. (nasdaq: oncr), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that president and chief executive officer, theodore (ted) ashburn, m.d., ph.d., will participate in a fireside chat at the jefferies global healthcare conference on wednesday, june 8, 2022 at 3:30 p.m. et in new york, ny.
2022-05-17 07:00:00 - Press Release
Oncorus To Present At The H.c. Wainwright Global Investment Conference
Cambridge, mass., may 17, 2022 (globe newswire) -- oncorus, inc. (nasdaq: oncr), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that president and chief executive officer, theodore (ted) ashburn, m.d., ph.d., will present an update on the company's progress at the h.c. wainwright global investment conference. the presentation will be available for on-demand viewing starting tuesday, may 24, 2022 at 7:00 a.m. et.
Latest News
2023-06-12 09:13:10 - InvestorPlace
Why Is Oncorus (ONCR) Stock Down 27% Today?
Oncorus (NASDAQ: ONCR ) stock is taking a beating on Monday after revealing plans for an upcoming special shareholder meeting. According to a filing with the Securities and Exchange Commission (SEC), Oncorus is seeking investor attendance at the meeting to vote on certain matters.
2023-06-05 12:56:06 - Zacks Investment Research
Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat
Oncorus (ONCR) decides to lay off nearly all of its workforce since it is facing challenges in raising additional capital. This lay off is expected to be completed by August 2023.
2022-11-23 08:00:00 - GlobeNewsWire
Oncorus to Participate in Upcoming Investor Conferences
ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming investor conferences:
2022-11-07 13:34:56 - Zacks Investment Research
Oncorus, Inc. (ONCR) Moves to Buy: Rationale Behind the Upgrade
Oncorus, Inc. (ONCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2022-09-26 07:00:00 - GlobeNewsWire
Oncorus to Present at Chardan's 6th Annual Genetic Medicines Conference
ANDOVER, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at Chardan's 6th Annual Genetic Medicines Conference on Monday, October 3, 2022 at 2:00 p.m. ET in New York, NY.
2022-09-06 07:00:00 - GlobeNewsWire
Oncorus to Present at the H.C. Wainwright 24th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 9:00 a.m. ET in New York, NY.
2022-07-13 11:32:56 - Zacks Investment Research
Here's Why Oncorus, Inc. (ONCR) Looks Ripe for Bottom Fishing
After losing some value lately, a hammer chart pattern has been formed for Oncorus, Inc. (ONCR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
2022-06-01 07:00:00 - GlobeNewsWire
Oncorus to Present at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 8, 2022 at 3:30 p.m. ET in New York, NY.
2022-05-17 07:00:00 - GlobeNewsWire
Oncorus to Present at the H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will present an update on the Company's progress at the H.C. Wainwright Global Investment Conference. The presentation will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. ET.
2022-03-21 07:00:00 - GlobeNewsWire
Oncorus to Present at the Maxim Group 2022 Virtual Growth Conference
CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference on Monday, March 28, 2022 at 12:30 p.m. ET. Dr. Ashburn will also present a corporate overview, which will become available for on-demand viewing on Monday, March 28, 2022 at 9:00 a.m. ET.